Skip to content
2000
Volume 9, Issue 3
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

Onconase, a member of the pancreatic ribonuclease A superfamily, is currently in Phase III clinical trials for treatment of unresectable malignant mesothelioma. The anticancer effect of onconase may relate to its intracellular target, a non-coding RNA. Some non- coding RNAs are aberrantly expressed in cancer cells. This discovery is creating new interest in drugs that target RNA. Conjugating onconase to agents that recognize tumor associated molecules further increases its potency and specificity. Analysis of onconase activity when directed to two different internalizing and one noninternalizing receptor reveals that the ideal targeting agents would rapidly enter lysosomal compartments before onconase escaped to the cytosol. Antibody-onconase conjugates are effective in preclinical models, cause little non-specific toxicities in mice and have favorable formulation properties. Understanding the reason for their potency coupled with understanding novel RNA-based mechanisms of tumor cell death will lead to improved variations of targeted onconase.

Loading

Article metrics loading...

/content/journals/cpb/10.2174/138920108784567272
2008-06-01
2025-07-11
Loading full text...

Full text loading...

/content/journals/cpb/10.2174/138920108784567272
Loading

  • Article Type:
    Research Article
Keyword(s): Antibody; Immunotoxin; Internalization; Onconase; Ribonuclease; RNase A
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test